Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang Huahai To Provide Finished Drug Product to Merck

publication date: Jul 29, 2008

Zhejiang Huahai Pharmaceutical Co., Ltd. signed an agreement with Merck to provide an unnamed finished product to the big pharma. The deal represents a move up for Huahai Pharma, which has traditionally provided APIs to western pharmaceutical companies, as well as finished drugs in China. Under the agreement, Huahai Pharma will formulate, produce and package the drug. Merck will distribute the product worldwide. More details...

Stock Symbols: (SHSE: 600521) (NYSE: MRK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital